OSR (NASDAQ:OSRH) & Entera Bio (NASDAQ:ENTX) Head-To-Head Analysis

Entera Bio (NASDAQ:ENTX) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Entera Bio and OSR, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1	0	4	1	2.83
OSR	1	0	0	0	1.00

Entera Bio presently has a consensus target price of $9.60, indicating a potential upside of 205.73%. Given Entera Bio’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Entera Bio is more favorable than OSR.

Profitability

This table compares Entera Bio and OSR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
OSR	-593.15%	-8.36%	-6.24%

Institutional & Insider Ownership

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 3.7% of Entera Bio shares are held by company insiders. Comparatively, 36.9% of OSR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Entera Bio and OSR”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44 million	($0.39)	-8.05
OSR	$1.81 million	2.86	-$27.06 million	($0.37)	-0.40

Entera Bio has higher earnings, but lower revenue than OSR. Entera Bio is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Entera Bio has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, OSR has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.